Malignant tumor and precancerosis (the cavity or superficial parts) patients
Conditions
Interventions
A:Hematoporphyrin injection, i.v. Laser therapy after 48-72 hours
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Male and female aged 18 years and more; 2) Patients with malignant tumor or precancerosis who have the detailed, clear case record; 3) Patients that never accept radiotherapy, chemotherapy, or chemotherapy drug withdrawal more than 4 weeks, or suspend radiotherapy in no-PDT- area more than 4 weeks; 4) Patients, with estimated lifetime more than 3 months, can tolerate photodynamic therapy and endoscopic therapy; 5) Patients agree to participate in the trial, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients are allergic to photosensitizers, cicatricial diathesis, or have history of porphyrin metabolic abnormalities; 2. Patients with heart disease whose cardiac function grade beyond?; 3. Patients with diseases of the blood system; 4. Liver and renal insufficiency: 1) The range of serum creatinine which is 1.5 times higher than normal; 2) Without hepatic metastasis, ALT or AST is 2.5 times higher than the normal reference range; With hepatic metastasis, ALT or AST is 5 times higher than the normal reference range (except in situ liver and biliary tract cancer); 3) Serum bilirubin is 1.5 times higher than the normal reference range (except the liver and biliary tract cancer); 5. Patients with tracheoesophageal fistula, or tumor has invaded the major blood vessels; 6. Patients have brain disease or abnormal judgment; 7. Drugs and/or alcohol abusers; 8. Pregnant or lactating women; 9. Patients have weakened immune system, immune inhibition or need glucocorticoid for long-term.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reactions; | — |
Countries
China
Contacts
Public ContactDu Hong
Sichuan Meidu Pharmaceutical Co., Ltd
Outcome results
None listed